Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor Phase 2a in Type 2 Diabetes
NCT01261494Phase 2Completed
- Sponsor
- Genfit
- Start
- Dec 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing GFT505 80mg with Matching placebo (2 arms). Primary endpoint: Glycosylated Haemoglobin A1c at 12 weeks. Started Dec 2010; status: completed.
02
Drugs
elafibranor
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01261494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01261494.